1선 항암화학요법에 반응이 없거나 재발한 위암환자에서 Etoposide. Doxorubicin, Cisplatin (EAP) 복합화학요법의 효과
Combination Chemotherapy with Etoposide. Doxorubicin, Cisplatin (EAP) for Recurred or Metastatic Gastric Cancer Refractory to Prior Chemotherapy
대한암학회지 2000년 32권 3호 p.524 ~ 530
조남국, 최대식, 박연희, 이승철, 유영진, 김성록,
소속 상세정보
조남국 ( Cho Nam-Kuk )
인제대학교 의과대학 상계백병원 내과학교실
최대식 ( Choi Tae-Sik )
인제대학교 의과대학 상계백병원 내과학교실
박연희 ( Park Yeon-Hee )
인제대학교 의과대학 상계백병원 내과학교실
이승철 ( Lee Seung-Chul )
인제대학교 의과대학 상계백병원 내과학교실
유영진 ( Yuh Young-Jin )
인제대학교 의과대학 상계백병원 내과
김성록 ( Kim Sung-Rok )
인제대학교 의과대학 상계백병원 내과
KMID : 0360320000320030524
Abstract
Purpose :We performed this study to evaluated the efficacy and the safety of EAp regimen as second line therapy for the recurred or metastatic gastric cancer unresponsive to 5-fluorouracil base chemotherapy.
Materials and Methods : Recurred or metastatic gastric cancer patients unresponsive to 5-flurouracil based regimen were entered into this trial. They were treated by EAp chemotherapy which consisted of etoposide 40 mg/㎡, doxorubicin 15 mg/㎡, and cisplatin 25 mg/㎡ Ⅳ during 3 days each every 3 weeks.
Results : From December 1994 to March 1998, Eighteen patients were enrolled in this protocol. Fourteen patients were evaluable for response. The overall response rate was 28.6% (95% CI: 11.7∼ 56.7%). The median response duration was 21 weeks. The median survival for all enrolled patients was 28 weeks. The major toxicity was myelosuppression. Among total of 69 cycle chemotherapy. WHO grade 3 or 4 granulocytopenia and thrombocytopenia were observed in 71.0% and 27.5%, respectively.
Conclusion :Second line therapy with EAP regimen was active for gastric cancer. Chemotherapy induced toxicities were moderate to severe.
키워드
Stomach neoplasm;Etoposide;Doxorubicin;Cisplatin;Chemotherapy;
원문 및 링크아웃 정보
등재저널 정보